Abstract:Objective This study was conducted to determine the prognostic factors of cervical adenocarcinoma.Methods Between July 2008 and June 2013, 211 consecutive patients were treated because of International Federation of Gynecology and Obstetrics(FIGO) stage IA-IVB cervical adenocarcinoma. Overall survival was analyzed by the Kaplan-Meier method.Results One-year OS rate was 96.2%,and 3-year OS rate was 88.6%,and 5-year OS rate was 74.7%.Patients’age,FIGO stage,postoperative clinicopathological factors such as depth of stromal invasion,number of pelvic lymph node metastasis and para-aortic lymph node metastasis,were analyzed to discriminate their prognostic role. In the univariate analysis, age,FIGO stge,deep stromal invasion, lymph-vascular space invasion, number of pelvic lymph node metastasis,para-aortic lymph node metastasis were associated with poorer survival(P< 0.05). In the cox analysis, age (RR=4.940,95%CI:1.925-12.678),pelvic lymph node metastasis(RR=2.391,95%CI:1.311-4.360),para-aortic lymph node metastasis (RR=6.344,95%CI:1.007-39.990)and FIGO stage(Ⅲ vs I,RR=5.315,95%CI:2.760-12.203;Ⅳ vs I,RR=9.932,95%CI:2.905-18.846)were independent prognostic factors of invasive cervical adenocarcinoma. Conclusion Early detection and early treatment is very important for cervical adenocarcinoma patients.Give the patient suitable and maybe more aggressive adjuvant therapy according to surgical pathology is helpful for imporving adenocarcinoma treatment.
[1]JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90. [2]ENDO D, TODO Y, OKAMOTO K, et al. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort[J]. J Gynecol Oncol, 2015, 26 (1):12-18. [3]BAEK M H, PARK J Y, KIM D, et al.Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery[J]. J Gynecol Oncol,2014,135(3):462-467. [4]IRIE T, KIGAWA J, MINAGAWA Y, et al. Prognosis and clinicopathological characteristics of Ib-IIbadenocarcinoma of the uterine cervix in patients who have had radical hysterectomy[J]. Eur J Surg Oncol, 2000,26(5):464-467. [5]LEE J Y, KIM Y T, KIM S, et al. Prognosis of cervical cancer in the era of concurrent chemoradiation from National Database in Korea: a comparison between squamous cell carcinoma and adenocarcinoma[J]. PLoS One, 2015, 10(12): e0144887. [6]VINH-HUNG V, BOURGAIN C, VLASTOS G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study[J].BMC Cancer, 2007(7):164. [7]FUJIWARA H, YOKOTA H, MONK B, et al.Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma[J]. Int J Gynecol Cancer, 2014,24(9 Suppl 3):S96-101. [8]STEHMAN F B, ALI S, KEYS H M, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma : follow-up of a Gynecologic Oncology Group trial[J]. Am J Obstet Gynecol, 2007,197(5): 503. e1-e6. [9]FIGO Committee on Gynecologic Oncology.FIGO staging for carcinoma of the vulva, cervix, and corpus uteri[J].Int J Gynaecol Obstet, 2014,125(2):97-98. [10] 钟钰平,沈建生,向吉萍,等. 农村妇女宫颈癌筛查结果[J].浙江预防医学,2012,24(11):53-54 [11]钱小萍,范水娟,姚慧. 15 881名农村妇女宫颈癌筛查结果[J].浙江预防医学,2014,26(6):627-628. [12] LAI C H, CHANG C J, HUANG H J, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery[J]. J Clin Oncol, 2007,25(24): 3628-3634. [13]DOUINE M, ROUE T, FIOR A, et al. Survival of patients with invasive cervical cancer in French Guiana, 2003-2008[J].Int J Gynaecol Obstet, 2014,125(2):166-167. [14]BAALBERGEN A, EWING-GRAHAM P C, HOP W C, et al. Prognostic factors in adenocarcinoma of the uterine cervix[J]. J Gynecol Oncol,2004,92(1):262-267. [15]喻芳明,陈亚侠,聂桂兰,等.宫颈癌患者盆腔淋巴结转移高危因素分析[J].浙江预防医学,2015,27(10):995-998.